Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Pipeline Review, H2 2016’, provides in depth analysis on Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eisai Co., Ltd.

Evotec AG

Heptares Therapeutics Limited

Johnson & Johnson

Merck & Co., Inc.

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Overview 7

Therapeutics Development 8

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Stage of Development 8

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Therapy Area 9

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Indication 10

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Companies 13

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development 20

Eisai Co., Ltd. 21

Evotec AG 22

Heptares Therapeutics Limited 23

Johnson & Johnson 24

Merck & Co., Inc. 25

Novartis AG 26

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles 27

DORA-12 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

HTL-6641 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

JNJ-42847922 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

lemborexant - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MK-8133 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

suvorexant - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Projects 44

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products 45

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Featured News & Press Releases 46

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 46

Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202 47

Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 47

Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 48

Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 49

Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 49

Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 50

Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 50

Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 51

Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 52

Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 53

Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 54

Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 54

Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 55

Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Actelion Ltd, H2 2016 20

Pipeline by Eisai Co., Ltd., H2 2016 21

Pipeline by Evotec AG, H2 2016 22

Pipeline by Heptares Therapeutics Limited, H2 2016 23

Pipeline by Johnson & Johnson, H2 2016 24

Pipeline by Merck & Co., Inc., H2 2016 25

Pipeline by Novartis AG, H2 2016 26

Dormant Projects, H2 2016 44

Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports